CA
CASI Pharmaceuticals, Inc.
CASIF · OTC
$0.11 +4.56% (+$0.00)
1M -22.07%
Market Cap $2.26M
P/E Ratio -
Div. Yield -
ROE -
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.11x
P/E N/A
EV/EBITDA N/A
Growth
9 /100
Declining Rev. growth 1.84%
Book val. growth 72.02%
EPS growth N/A
Profitability
22 /100
Weak Gross margin 59.97%
Net margin 218.55%
FCF margin 0.00%
Quality
74 /100
Excellent ROIC 759.62%
ROA 208.70%
Asset turnover 0.95x
Debt
0 /100
High Current ratio 0.15x
Int. coverage -100.15x
Debt/Equity N/A
Stability
35 /100
Moderate Beta 1.40x
Rev. volatility 35.61%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CASIF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Cory
Employees
214
Headquarters
Beijing
Upcoming events
13 NOV
Earnings
Upcoming earnings report